MAPT and Lewy body dementia: Collectively, these findings and others (Coughlin et al., 2020; Gomperts et al., 2016) suggest a potential underlying role of tau in the disease course of DLB and warrant further longitudinal studies, ideally enrolling prodromal DLB patients to better understand if and how tau burden contributes to the disease course of Lewy body diseases.